GU Ventures portfolio company Pretzel Therapeutics wins FDA clearance to start PX578 Phase 2 POLG disease study in 2026

PUBT · 3d ago
GU Ventures portfolio company Pretzel Therapeutics wins FDA clearance to start PX578 Phase 2 POLG disease study in 2026
  • Pretzel Therapeutics, a GU Ventures portfolio company, secured FDA clearance to advance PX578 into a Phase 2 POLG disease trial.
  • Phase 2 study, POLARIS, is slated to start in late 2026, targeting safety, tolerability, and efficacy in patients.
  • Pretzel completed a Phase 1 trial of PX578 in healthy volunteers, positioning the program for patient testing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GU Ventures AB published the original content used to generate this news brief on September 02, 2026, and is solely responsible for the information contained therein.